Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab
Multispecific antibody therapeutic developer Numab – run by two former Esbatech executives – has come of age with a deal in the IO space that validates its technology. Could this mean bispecific programs have had their day?
You may also be interested in...
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
Avillion – which seeks co-development deals for products that otherwise could languish in busy big pharma pipelines – is taking on development of Merck's early-stage psoriasis drug, M1095, despite originator Ablynx having opted out of a co-development arrangement with the German firm for the drug four years earlier.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.